These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 12975335)

  • 1. Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19.
    Yu BN; Chen GL; He N; Ouyang DS; Chen XP; Liu ZQ; Zhou HH
    Drug Metab Dispos; 2003 Oct; 31(10):1255-9. PubMed ID: 12975335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19.
    Wang JH; Liu ZQ; Wang W; Chen XP; Shu Y; He N; Zhou HH
    Clin Pharmacol Ther; 2001 Jul; 70(1):42-7. PubMed ID: 11452243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phenotype-genotype relationship and clinical effects of citalopram in Chinese patients.
    Yin OQ; Wing YK; Cheung Y; Wang ZJ; Lam SL; Chiu HF; Chow MS
    J Clin Psychopharmacol; 2006 Aug; 26(4):367-72. PubMed ID: 16855453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and bioavailability comparison of generic and branded citalopram 20 mg tablets: an open-label, randomized-sequence, two-period crossover study in healthy Chinese CYP2C19 extensive metabolizers.
    Jiang T; Rong Z; Xu Y; Chen B; Xie Y; Chen C; Lu Y; Shen Y; Li H; Sun J; Chen H
    Clin Drug Investig; 2013 Jan; 33(1):1-9. PubMed ID: 23179471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of effect of Ginkgo biloba on voriconazole pharmacokinetics in Chinese volunteers identified as CYP2C19 poor and extensive metabolizers.
    Lei HP; Wang G; Wang LS; Ou-yang DS; Chen H; Li Q; Zhang W; Tan ZR; Fan L; He YJ; Zhou HH
    Ann Pharmacother; 2009 Apr; 43(4):726-31. PubMed ID: 19299322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYP2C9, but not CYP2C19, polymorphisms affect the pharmacokinetics and pharmacodynamics of glyburide in Chinese subjects.
    Yin OQ; Tomlinson B; Chow MS
    Clin Pharmacol Ther; 2005 Oct; 78(4):370-7. PubMed ID: 16198656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir.
    Mikus G; Schöwel V; Drzewinska M; Rengelshausen J; Ding R; Riedel KD; Burhenne J; Weiss J; Thomsen T; Haefeli WE
    Clin Pharmacol Ther; 2006 Aug; 80(2):126-35. PubMed ID: 16890574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of CYP2C19 genetic polymorphism on the pharmacokinetics and pharmacodynamics of omeprazole in Chinese people.
    Hu XP; Xu JM; Hu YM; Mei Q; Xu XH
    J Clin Pharm Ther; 2007 Oct; 32(5):517-24. PubMed ID: 17875119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype.
    Qiao HL; Hu YR; Tian X; Jia LJ; Gao N; Zhang LR; Guo YZ
    Eur J Clin Pharmacol; 2006 Feb; 62(2):107-12. PubMed ID: 16402242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers.
    Ko JW; Jang IJ; Shin JG; Nam SK; Shin SG; Flockhart DA
    Clin Pharmacol Ther; 1999 Jun; 65(6):606-14. PubMed ID: 10391666
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of the CYP2C19 oxidation polymorphism on fluoxetine metabolism in Chinese healthy subjects.
    Liu ZQ; Cheng ZN; Huang SL; Chen XP; Ou-Yang DS; Jiang CH; Zhou HH
    Br J Clin Pharmacol; 2001 Jul; 52(1):96-9. PubMed ID: 11453896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omeprazole as a CYP2C19 marker in Chinese subjects: assessment of its gene-dose effect and intrasubject variability.
    Yin OQ; Tomlinson B; Chow AH; Waye MM; Chow MS
    J Clin Pharmacol; 2004 Jun; 44(6):582-9. PubMed ID: 15145965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterozygous mutation in CYP2C19 significantly increases the concentration/dose ratio of racemic citalopram and escitalopram (S-citalopram).
    Rudberg I; Hendset M; Uthus LH; Molden E; Refsum H
    Ther Drug Monit; 2006 Feb; 28(1):102-5. PubMed ID: 16418702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes.
    Rochat B; Amey M; Gillet M; Meyer UA; Baumann P
    Pharmacogenetics; 1997 Feb; 7(1):1-10. PubMed ID: 9110356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of cytochrome P2C19 in R-warfarin pharmacokinetics and its interaction with omeprazole.
    Uno T; Sugimoto K; Sugawara K; Tateishi T
    Ther Drug Monit; 2008 Jun; 30(3):276-81. PubMed ID: 18520598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enantioselective analysis of citalopram and its metabolites in postmortem blood and genotyping for CYD2D6 and CYP2C19.
    Holmgren P; Carlsson B; Zackrisson AL; Lindblom B; Dahl ML; Scordo MG; Druid H; Ahlner J
    J Anal Toxicol; 2004 Mar; 28(2):94-104. PubMed ID: 15068562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response.
    Tsai MH; Lin KM; Hsiao MC; Shen WW; Lu ML; Tang HS; Fang CK; Wu CS; Lu SC; Liu SC; Chen CY; Liu YL
    Pharmacogenomics; 2010 Apr; 11(4):537-46. PubMed ID: 20350136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of CYP2C19 in amitriptyline N-demethylation in Chinese subjects.
    Jiang ZP; Shu Y; Chen XP; Huang SL; Zhu RH; Wang W; He N; Zhou HH
    Eur J Clin Pharmacol; 2002 May; 58(2):109-13. PubMed ID: 12012142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine.
    Miura M; Tada H; Yasui-Furukori N; Uno T; Sugawara K; Tateishi T; Suzuki T
    Br J Clin Pharmacol; 2005 Jul; 60(1):61-8. PubMed ID: 15963095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of CYP2C19 and CYP3A4 to the formation of the active nortilidine from the prodrug tilidine.
    Grün B; Merkel U; Riedel KD; Weiss J; Mikus G
    Br J Clin Pharmacol; 2012 Nov; 74(5):854-63. PubMed ID: 22381043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.